Personalised medicine is increasingly moving from a specialist scientific discussion to a central question for health policy: how can health systems use genomic, molecular, clinical and digital information to deliver more targeted, effective and equitable care?

A recent policy brief from the European Observatory on Health Systems and Policies, Personalized medicine for healthier populations: Key considerations for policy-makers, underlines that personalised medicine is not only about expensive advanced therapies. It can also support targeted prevention, earlier diagnosis, more cost-effective treatment selection and better use of health-system resources.

This distinction is important. Too often, personalised medicine is framed only through the lens of high-cost innovation. But its wider value lies in matching the right intervention to the right patient at the right time, whether that means identifying inherited risk, selecting the most appropriate diagnostic test, avoiding ineffective treatment, supporting clinical trial access or improving long-term disease prevention.

The challenge is no longer simply whether the science is advancing. It is whether health systems are ready to implement it.

The Observatory’s brief highlights several conditions that must be in place if personalised medicine is to benefit populations, rather than only selected groups of patients in well-resourced centres. These include strong governance, trusted use of genomic and health data, investment in infrastructure, high-quality electronic health records, accredited testing facilities, validated clinical decision support tools, and a workforce trained in genomics, digital health, data management, ethics and interdisciplinary care.

This reflects a growing policy reality: personalised medicine depends on systems, not only technologies. Genomic sequencing, biomolecular diagnostics, biobanks, digital pathology, interoperable data systems and artificial intelligence can all contribute to more precise care, but only if they are embedded within trusted, regulated and equitable health systems.

Trust is central. Personalised medicine requires the collection and use of highly sensitive personal and genomic data. Patients and citizens must be confident that their data will be protected, used responsibly and governed transparently. This means clear rules on confidentiality, protection against discrimination, cybersecurity, public involvement, meaningful consent models and strong communication to address gaps in health literacy.

The ethical, legal and social dimensions of personalised medicine cannot be treated as an afterthought. They are part of the infrastructure required for implementation. Without public confidence, data sharing will remain limited, research will be constrained, and the promise of personalised approaches will not be fully realised.

The policy discussion is also becoming more urgent at global level. In May 2026, WHO Member States approved a landmark resolution on precision medicine, placing equity at the centre of the agenda. The resolution recognises the potential of clinical, molecular and genomic data to guide prevention, diagnosis and treatment, while also warning that limited laboratory capacity, workforce shortages and under-representation in genomic datasets could widen inequalities if countries do not act.

For Europe, this is a timely reminder that leadership in personalised medicine should not be measured only by research excellence or regulatory approval. It should be measured by whether patients across countries and regions can access validated diagnostics, receive appropriate interpretation of results, and benefit from personalised prevention and treatment pathways in routine care.

Cost and reimbursement remain major barriers. Advanced diagnostics and therapies can place pressure on health budgets, while traditional evidence-generation and reimbursement models may not always fit rapidly evolving technologies. The Observatory points to the need for early dialogue between manufacturers, regulators and health technology assessment bodies, as well as broader use of real-world data, innovative trial designs, public–private and public–public collaboration, and flexible reimbursement approaches such as managed entry agreements.

This is particularly relevant in oncology, rare diseases, cardiometabolic disease and other areas where innovation is moving quickly but access remains uneven. A patient may be eligible for a targeted therapy or advanced diagnostic approach in scientific terms, but still face delays if testing is unavailable, reimbursement is unclear, data systems are fragmented, or clinical pathways are not aligned.

The European Commission’s work on health data and citizens’ control over data is part of this wider shift. The future of personalised medicine will depend on whether Europe can connect data protection with data use, innovation with affordability, and research with implementation.

A related European Observatory webinar in June 2026 asked a direct question: what do health policy-makers need to know about personalised medicine? The answer is increasingly clear. Policymakers do not need only a scientific explanation of genomics or precision therapies. They need to understand the practical choices that determine whether personalised medicine becomes part of health-system transformation or remains a series of isolated innovations.

Those choices include how to fund diagnostics, how to build laboratory and digital infrastructure, how to train professionals, how to validate AI-enabled decision support, how to involve patients and the public, how to generate evidence for payers, and how to ensure that access does not depend on geography, income or institutional capacity.

For EAPM, the message is consistent with the broader personalised medicine agenda: innovation must be connected to access. The promise of personalised medicine will only be realised if health systems are able to identify patients, test appropriately, interpret results, act on the findings and measure whether outcomes and access have improved.

Personalised medicine is no longer a future concept. It is already reshaping prevention, diagnostics and treatment. The policy task now is to ensure that this transformation is responsible, trusted, sustainable and equitable.

Sources:

1. European Observatory on Health Systems and Policies — Personalized medicine for healthier populations: Key considerations for policy-makers, Policy Brief 69, 8 July 2025.
2. European Observatory on Health Systems and Policies — Webinar: Personalized medicine: What do health policy makers need to know?, 18 June 2026.
3. WHO — Seventy-ninth World Health Assembly – Daily update: 22 May 2026, including the landmark resolution on precision medicine.
4. PAHO/WHO — WHO advances precision medicine as a global health priority, 19 June 2026.